Rick Gonzalez, AbbVie CEO
June 15, 2023 03:39 PM EDTUpdated 04:01 PM
Pharma

Ab­b­Vie touts Skyrizi ul­cer­a­tive col­i­tis da­ta as it eyes an­oth­er in­di­ca­tion

Nicole DeFeudis

Editor

Ab­b­Vie has tout­ed Skyrizi as a key pil­lar of its fu­ture be­yond Hu­mi­ra, and on Thurs­day, the com­pa­ny read out re­sults sug­gest­ing the IL-23 in­hibitor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times